Seeking Alpha

Merck (MRK) says the U.S. District Court in New Jersey has ruled against it in a patent...

Merck (MRK) says the U.S. District Court in New Jersey has ruled against it in a patent infringement suit against Apotex Corp., saying its Nasonex patent would not be infringed by a competing product. The patent at issue covers mometasone furoate monohydrate, the active ingredient in Nasonex which Merck says provides exclusivity until April 3, 2018. Apotex is currently seeking FDA approval to sell a generic version. The drug giant will likely appeal the decision. Shares -0.2% AH.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs